KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million. On the news front, according to an announcement on KEYMED BIO-B's official WeChat account, the company and its partner Ouro Medicines Ltd. recently announced that their BCMA×CD3 bispecific antibody, CM336 (OM336), has been granted Fast Track Designation (FTD) by the US FDA for the treatment of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP). The granting of Fast Track Designation for CM336 in both AIHA and ITP indications highlights the urgent need for innovative treatment options for these diseases and further demonstrates CM336's therapeutic potential in autoimmune disorders. Previously, KEYMED BIO entered into an exclusive license agreement with Ouro Medicines Ltd., granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding Mainland China, Hong Kong, Macau, and Taiwan). CM336 has already received Orphan Drug Designation (ODD) from the FDA for the treatment of both AIHA and ITP.